Valbiotis Logo

Valbiotis

Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.

ALVAL | PA

Overview

Corporate Details

ISIN(s):
FR0013254851
LEI:
969500VP4JBJCF0MOP60
Country:
France
Address:
RUE PAUL VATINE, 17180 PERIGNY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valbiotis is a research and development company committed to scientific innovation for the prevention and management of metabolic and cardiovascular diseases. The company specializes in developing and marketing plant-based, clinically tested dietary supplements and active substances. Its core focus is on major health risk factors including prediabetes, dyslipidemia, arterial hypertension, and metabolic liver diseases. Leveraging its botanical expertise, Valbiotis creates multi-target active substances that act on multiple physiological pathways. The company's product portfolio, including the ValbiotisPRO® range, is distributed through pharmacies and is aimed at both healthcare professionals and consumers seeking scientifically validated natural health solutions.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Valbiotis and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 11:40
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-08-11 17:30
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 165.4 KB
2025-07-03 17:45
Regulatory News Service
VALBIOTIS SA: Bilan semestriel du contrat de liquidité
French 359.3 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 19.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue …
English 470.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 6,9…
French 419.2 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its 6.9 million rights issue e…
English 142.5 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 579.9 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le lancement d’une augmentation de capital avec…
French 511.1 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 305.6 KB
2025-06-02 22:48
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 131.2 KB
2025-06-02 22:48
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.1 KB
2025-05-22 17:40
Earnings Release
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
English 235.0 KB
2025-05-22 17:40
Regulatory News Service
VALBIOTIS SA: Valbiotis commercialisera le 2 juin prochain  sa solution Valbio…
French 201.0 KB

Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valbiotis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 N/A Other Other 10,400 46,072.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.